DHFR-IN-4
CAS No. 2820126-49-4
DHFR-IN-4( —— )
Catalog No. M35563 CAS No. 2820126-49-4
DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with anti-tumor activity, which also inhibits EGFR and HER2, and is useful for studying pancreatic cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 523 | In Stock |
|
| 10MG | 660 | In Stock |
|
| 25MG | 858 | In Stock |
|
| 50MG | 1144 | In Stock |
|
| 100MG | 1553 | In Stock |
|
| 200MG | 2093 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDHFR-IN-4
-
NoteResearch use only, not for human use.
-
Brief DescriptionDHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with anti-tumor activity, which also inhibits EGFR and HER2, and is useful for studying pancreatic cancer.
-
DescriptionDHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with an IC50 value of 123 nM. DHFR-IN-4 also has inhibitory activity against EGFR and HER2 with IC50s of 246 nM and 357 nM, respectively. DHFR-IN-4 has remarkable broad spectrum cytotoxic potency against cancer cells.
-
In VitroDHFR-IN-4 (compound 42) (0-100 μM; 72 h) shows remarkable broad spectrum cytotoxic potency against HepG2, MCF-7, HCT-116, PC3 and HeLa.Cell Cytotoxicity Assay Cell Line:HepG2, MCF-7, HCT-116, PC3 and HeLa Concentration:0-100 μM Incubation Time:72 h Result:Exhibited antiproliferative activity against HepG2, MCF-7, HCT-116, PC3 and HeLa with IC50s of 9.67±0.7 μM, 8.46±0.7 μM, 13.24±0.9 μM, 11.17±1.0 μM and 6.90±0.5 μM.
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetDHFR
-
RecptorDHFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2820126-49-4
-
Formula Weight371.46
-
Molecular FormulaC18H21N5O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NN)C1=CSC2=NC(=C(C=3C=CC(=CC3)C)N21)CN4CCOCC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sabry MA, et al. New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity. Eur J Med Chem. 2022 Aug 10;241:114661.?
molnova catalog
related products
-
Piritrexim
Piritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma and metastatic breast cancer.
-
Brodimoprim
Brodimoprim is an inhibitor of dihydrofolate reductase(DHFR). Brodimoprim is also a long-acting broad-spectrum antibacterial agent characterized by a good pharmacokinetic profile.
-
WR99210
WR99210 is effective against the most pyrimethamine-resistant Plasmodium falciparum strains.
Cart
sales@molnova.com